178 related articles for article (PubMed ID: 28641336)
1. Suppression of Forkhead Box Protein O1 (FOXO1) Transcription Factor May Promote Adrenocortical Tumorigenesis.
Stenman A; Murtha T; Korah R; Carling T
Horm Metab Res; 2017 Aug; 49(8):631-637. PubMed ID: 28641336
[TBL] [Abstract][Full Text] [Related]
2. A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis.
Cheng JY; Brown TC; Murtha TD; Stenman A; Juhlin CC; Larsson C; Healy JM; Prasad ML; Knoefel WT; Krieg A; Scholl UI; Korah R; Carling T
BMC Cancer; 2017 Mar; 17(1):164. PubMed ID: 28249601
[TBL] [Abstract][Full Text] [Related]
3. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
[TBL] [Abstract][Full Text] [Related]
4. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
[TBL] [Abstract][Full Text] [Related]
5. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
[TBL] [Abstract][Full Text] [Related]
7. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
8. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions.
Blanes A; Diaz-Cano SJ
Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T
Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
[TBL] [Abstract][Full Text] [Related]
11. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
12. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome.
Ronchi CL; Sbiera S; Altieri B; Steinhauer S; Wild V; Bekteshi M; Kroiss M; Fassnacht M; Allolio B
Endocr Relat Cancer; 2015 Aug; 22(4):531-43. PubMed ID: 25979380
[TBL] [Abstract][Full Text] [Related]
13. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
[TBL] [Abstract][Full Text] [Related]
14. STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.
Aronova A; Min IM; Crowley MJP; Panjwani SJ; Finnerty BM; Scognamiglio T; Liu YF; Whitsett TG; Garg S; Demeure MJ; Elemento O; Zarnegar R; Fahey TJ
Ann Surg Oncol; 2018 Mar; 25(3):792-800. PubMed ID: 29214451
[TBL] [Abstract][Full Text] [Related]
15. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
[TBL] [Abstract][Full Text] [Related]
16. SLC12A7 alters adrenocortical carcinoma cell adhesion properties to promote an aggressive invasive behavior.
Brown TC; Murtha TD; Rubinstein JC; Korah R; Carling T
Cell Commun Signal; 2018 Jun; 16(1):27. PubMed ID: 29884238
[TBL] [Abstract][Full Text] [Related]
17. Association of Nrf2 expression and mutation with Weiss and Helsinki scores in adrenocortical carcinoma.
Kamai T; Murakami S; Arai K; Ishida K; Kijima T
Cancer Sci; 2022 Jul; 113(7):2368-2377. PubMed ID: 35467062
[TBL] [Abstract][Full Text] [Related]
18. Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas.
Pereira SS; Máximo V; Coelho R; Batista R; Soares P; Guerreiro SG; Sobrinho-Simões M; Monteiro MP; Pignatelli D
J Cell Biochem; 2017 Aug; 118(8):2064-2071. PubMed ID: 27886397
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for epithelial-mesenchymal transition in adrenocortical tumors?
Bulzico D; Faria PAS; Maia CB; de Paula MP; Torres DC; Ferreira GM; Pires BRB; Hassan R; Abdelhay E; Vaisman M; Vieira Neto L
Endocrine; 2017 Nov; 58(2):276-288. PubMed ID: 28887601
[TBL] [Abstract][Full Text] [Related]
20. LncRNA HOTAIR participates in the development and progression of adrenocortical carcinoma via regulating cell cycle.
Yan ZC; He L; Qiu JH; Deng WT; Lu JR; Yuan Z; Liu DJ; Zheng RQ; Jiang W
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6640-6649. PubMed ID: 30402836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]